{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:43:00Z","timestamp":1793209380717,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ygyno.2019.11.012","type":"journal-article","created":{"date-parts":[[2019,12,8]],"date-time":"2019-12-08T23:50:15Z","timestamp":1575849015000},"page":"308-314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies"],"prefix":"10.1016","volume":"156","author":[{"given":"I.B.","family":"Vergote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Peen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Umajuridze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mau-Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kranich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Van Nieuwenhuysen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Haslund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Nottrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.N.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Concin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.J.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Rashal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Crochiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Landesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Shacham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kauffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.11.012_bib1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study","volume":"3","author":"Global Burden of Disease Cancer Collaboration","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2019.11.012_bib2","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.18632\/oncotarget.14021","article-title":"Chemoresistance and targeted therapies in ovarian and endometrial cancers","volume":"8","author":"Brasseur","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2019.11.012_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2014.03.002","article-title":"Atomic basis of CRM1-cargo recognition, release and inhibition","volume":"27","author":"Fung","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ygyno.2019.11.012_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1158\/2159-8290.CD-13-1005","article-title":"Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy","volume":"4","author":"Tan","year":"2014","journal-title":"Cancer Discov."},{"issue":"85 1\u20139","key":"10.1016\/j.ygyno.2019.11.012_bib5","article-title":"Nucleo-cytoplasmic transport as a therapeutic target of cancer","volume":"7","author":"Gravina","year":"2014","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.012_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","article-title":"Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents","volume":"7","author":"Parikh","year":"2014","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.012_bib7","doi-asserted-by":"crossref","first-page":"960","DOI":"10.4161\/cc.8.7.8093","article-title":"The eukaryotic translation initiation factor 4E (eIF4E) and HuR RNA operons collaboratively regulate the expression of survival and proliferative genes","volume":"8","author":"Topisirovic","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ygyno.2019.11.012_bib8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/imr.12240","article-title":"The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled","volume":"263","author":"Osborne","year":"2015","journal-title":"Immunol. Rev."},{"issue":"7353","key":"10.1016\/j.ygyno.2019.11.012_bib9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ygyno.2019.11.012_bib10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ygyno.2019.06.016","article-title":"Comprehensive genomic profiling of recurrent endometrial cancer: implications for selection of systemic therapy","volume":"154","author":"Prendergast","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2019.11.012_bib11","doi-asserted-by":"crossref","first-page":"800","DOI":"10.7150\/ijms.34172","article-title":"Identification of key genes and pathways in cervical cancer by bioinformatics analysis","volume":"16","author":"Wu","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.ygyno.2019.11.012_bib12","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-16-1333","article-title":"Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer","volume":"23","author":"Chen","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.11.012_bib13","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-Class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors","volume":"34","author":"Abdul Razak","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2019.11.012_bib14","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2019.11.012_bib15","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-15-0978","article-title":"XPO1 inhibition enhances radiation response in preclinical models of rectal cancer","volume":"22","author":"Ferreiro-Neira","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.11.012_bib16","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood-2014-10-607648","article-title":"Decitabine priming enhances the anti-leukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia","volume":"125","author":"Ranganathan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2019.11.012_bib17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/1535-7163.MCT-16-0498","article-title":"The exportin-1 inhibitor selinexor exerts superior antitumor activity when combined with T-cell checkpoint inhibitors","volume":"16","author":"Farren","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2019.11.012_bib18","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-017-0878-6","article-title":"Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer","volume":"19","author":"Arango","year":"2017","journal-title":"Breast Cancer Res."},{"issue":"15","key":"10.1016\/j.ygyno.2019.11.012_bib19","article-title":"Selinexor, a selective inhibitor of nuclear export (SINE) compound, shows enhanced antitumor activity in combination with the PARP inhibitor, olaparib, in models of triple-negative breast cancer","volume":"75","author":"Marijon","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2019.11.012_bib20","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1124\/jpet.110.173146","article-title":"Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells","volume":"335","author":"Tsai","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ygyno.2019.11.012_bib21","series-title":"Poster Presented at: European Society for Medical Oncology Congress","article-title":"Circulating tumor cell number predicts time to progression in patients (TTP) with heavily pretreated gynecological cancers treated with selinexor (SEL)","author":"Crochiere","year":"2016"},{"key":"10.1016\/j.ygyno.2019.11.012_bib22","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1200\/JCO.2016.67.6346","article-title":"Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma","volume":"34","author":"Gounder","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.11.012_bib23","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.18632\/oncotarget.6495","article-title":"A\u00a0method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds","volume":"7","author":"Crochiere","year":"2016","journal-title":"Oncotarget"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819316634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819316634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:49:22Z","timestamp":1758772162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819316634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0090825819316634"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.11.012","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}